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Carbamazepine (CBZ) is a widely employed anti-seizure medication that crosses the blood-
brain barrier (BBB) to exert its anti-convulsant action. The effects of CBZ on components of 
the BBB have yet to be completely delineated.  Hence the current study evaluated the effects 
of CBZ upon mitochondrial functionality of BBB-derived microvascular endothelial cells 
isolated from Albino rats.  The influence of CBZ on cell viability and barrier functions were 
evaluated by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), lactate 
dehydrogenase, and electrophysiological assays over a drug concentration range of 0.1-1000 
µM.  Bioenergetics effects were measured via ATP production, mitochondrial complexes I and 
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III activities, lactate production, and oxygen consumption rates (OCRs), and mitochondrial 
membrane potential, fluidity and lipid content. CBZ was cytotoxic to microvascular endothelial 
cells in a concentration and duration dependent manner. CBZ significantly diminished the 
endothelial cell’s barrier functions, and impacted upon cellular bioenergetics: reducing 
mitochondrial complex activities with a parallel decrease in OCRs and increased anaerobic 
lactate production.  CBZ significantly decreased mitochondrial membrane potential and 
induced an increase of membrane fluidity and decrease in levels of mitochondrial saturated and 
unsaturated fatty acids.  In summary, CBZ disrupted functional activity of BBB endothelial 
cells via damage and modification of mitochondria functionality at therapeutically relevant 
concentrations.  
Keywords: Blood-brain barrier; Carbamazepine, Microvascular endothelial cells; 
Mitochondria. 
Introduction: Carbamazepine (CBZ) is commonly employed as an anti-seizure drug and 
treatment for neuropathic pain (Albani et al., 1995; Alrashood, 2016; Gierbolini et al., 2016). 
It is a first-line medication for partial or generalized tonic and mixed convulsions, used as a 
treatment for trigeminal neuralgia, and also utilized as a mood stabilizer (Albani et al., 1995; 
Wiffen et al., 2014).  Its mode of action is not completely understood but is primarily related 
to blockade of pre-synaptic voltage-gated sodium channels to decrease hyperexcitability of 
neurons (Macdonald and Kelly, 1995; Ambrosio et al., 2002; Sheets et al., 2008; Sills and 
Rogawski, 2020). CBZ also affects other channels, receptors, as well as signaling pathways 
such as those downstream of adenylyl cyclase activation (Chen et al., 1996; Ambrosio et al., 
2002), but a comprehensive evaluation of CBZ signaling has yet to be undertaken.    
CBZ is a dibenzoazepine with structural similarities to tricyclic antidepressants.  It is a 
neutral molecule of molecular mass 236, with high lipophilic character (Beig et al., 2016) 
(Figure 1); properties well suited for traversing the blood-brain barrier (BBB) to exert its 
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central effects. The BBB is composed of endothelial cells that line the vessels as well as other 
cell types including pericytes and glial cells such as astrocytes that collectively form a 
protective barrier between the blood and the CNS (Abbott et al., 2010). The unique properties 
of the microvessels of the CNS include endothelial cells that are mitochondria-rich, and operate 
without fenestration to limit undesired transport of molecules across the BBB (Yazdani et al., 
2019).  Furthermore, these cells express surface transporter proteins from the ATP-binding 
cassette (ABC) transporter superfamily, including P-glycoprotein, that are coupled to ATP 
usage to drive unidirectional (efflux) movement of endogenous molecules, as well as 
xenobiotics (Abbott et al., 2010; Daneman, 2012, Yazdani et al., 2019).  Therefore maintenance 
of ATP levels is critical to the performance and integrity of the BBB.  
ATP is synthesized by mitochondria via the process of oxidative phosphorylation, and 
involves the passage of electrons along an electron transport chain (ETC), and coupling of 
proton transport with ATP synthesis. The ETC is comprised of a series of protein complexes 
in the inner mitochondrial membrane that transfer electrons to reduce oxygen to water.  This 
electron transport is coupled to directional flow of protons across the mitochondrial membrane, 
generating a proton motive force that supports ATP synthesis via ATP synthase (complex V) 
(Kuhlbrant, 2015).  
CBZ has a plasma half-life of 30-40 hours, and although widely prescribed, operates 
with only a relatively narrow therapeutic index.  Clinical efficacy is achieved at steady-state 
blood levels of 4-12 µg/ml (17-51 µM), but toxicity is observed at levels above 15-18 µg/ml 
(64-76 µM), is notable at 40 µg/ml (>170 µM), with CBZ potentially lethal at 50 µg/ml (212 
µM) (Hojer et al., 1993; Winek et al., 2001). At toxic or overdose levels, CBZ presents with a 
wide range of symptomology including ataxia, ventricular arhythmias, seizures, respiratory 
depression, and induction of coma (Spiller et al., 1990; Spiller, 2001).  
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Furthermore, even within its therapeutic window, CBZ can exhibit multiple adverse 
drug effects (ADRs) including hypersensitivity responses; that for some individuals relates to 
genetic polymorphisms in human leukocyte antigen (HLA) alleles, and differential efficacy 
that relates to pharmacogenetics of cytochrome P450 enzymes required for phase I and II CBZ 
metabolism (Albani et al., 1995; Jaramillo et al., 2014; Fricke-Galindo et al., 2018).   
Hitherto, a number of the studies have considered the cytotoxicity or genotoxicity of 
CBZ, although some of these analyses have only focused upon its potential damage as a 
contaminant to fresh water systems due to its stability and lack of biodegradation (Ferrari et 
al., 2003, Laville et al., 2004, Li et al., 2010a,b; Han et al., 2018; Fraz et al., 2018,2019; Shao 
et al., 2019).  One mechanism of CBZ cytotoxicity is through induction of reactive oxygen 
species (ROS) (Li et al. 2010a,b; Shao et al., 2019; Elmorsy E, 2020), although this has not 
been observed in all cell studies (Laville et al., 2004).  However, these studies have not 
specifically considered an effect of CBZ upon mitochondrial bioenergetics, or assessed the 
influence of the drug upon barrier properties of endothelial cells.  To cover this knowledge gap, 
we have examined bioenergetic and barrier properties of isolated microvascular endothelial 
cells from Wistar albino rats after treatment with CBZ at therapeutic as well as toxic drug 
concentrations. 
2. Materials: 
2.1. Chemicals and reagents: Carbamazepine (CBZ) (5H-dibenzo[b,f]azepine-5-
carboxamide), 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and all 
other chemicals used in this study were purchased from Sigma (St. Louis, MO, USA), unless 
another source is mentioned. The media components, Ham’s F-10 nutrient mixture, fetal bovine 
serum, and horse serum were obtained from Gibco BRL (Grand Island, NY, USA). CBZ was 
dissolved in DMSO at a stock concentration of 1 mM. Collagenase/dispase and basic fibroblast 
growth factor (bFGF) were obtained from Roche Molecular Biochemicals (Indianapolis, IN, 
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USA).  For oxygen consumption rate, modified Hank’s was prepared following Daunt et al. 
(2005) (5.6 mM KCl, 138 mM NaCl, 4.2 mM NaHCO3, 1.2 mM NaH2PO4, 2.6 mM CaCl2, 1.2 
mM MgCl2, 10 mM Na-HEPES (pH 7.4), and 0.1% (w/v) bovine serum albumin (BSA). 
 
2.2. Animals: Wistar Albino rats were used for preparation of microvascular endothelial cells 
of the BBB.  The use of rats for this study was approved by an institutional research board from 
the Mansoura Faculty of Medicine (Study reference: R2.16/12/18). Rats were sacrificed under 
anesthesia with sodium pentobarbital. 
3. Methods:  
3.1. Isolation of rat cerebral microvascular endothelial cells (rCMECs) and CBZ treatments: 
For isolation and culture of rCMECs the method of Calabria et al. (2006) was followed with 
modifications as described by Liu et al. (2014), and published previously (Elmorsy et al. 2017). 
For endothelial cell purification, 33% continuous Percoll gradients were used.  Cells were 
washed and plated on 35 mm collagen IV/fibronectin-coated plates (both at 0.1 mg/ml). For 
cell culturing, rCMECs were maintained in Endothelial Cell Medium supplemented with 
4µg/ml puromycin and 100mg/ml heparin for 3 days. Thereafter, media were prepared without 
puromycin. For isolated rCMECs characterization, Western blotting was conducted for 
expression of both P-glycoproteins and breast cancer resistant transporters proteins to confirm 
expression properties of microvascular endothelial cells, as published previously (Elmorsy et 
al., 2017) (results not included).  CBZ (or vehicle control) was applied directly to cells within 
culture media.  The proportion of CBZ taken up by cells was not quantified. 
3.2. Cytotoxicity assays:  
3.2.1. MTT assays: Isolated cells were seeded at 103 cells/well in 96 well plates and cultured 
until 90% confluent before treatment with CBZ at 1, 10, 100, and 1000 µM concentrations for 
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3, 6, 12, 24, or 48 hours.  Reduction of MTT substrate was quantified spectrophotometrically 
at 590 nm, according to the manufacturer’s protocol.  All assay data points were generated 
from at least 3 separate experiments, with each experiment containing three replicates at each 
CBZ concentration.  Cell viability was quantified relative to vehicle controls set at 100% 
viability.  
3.2.2. Lactate dehydrogenase (LDH) assays: Cells were prepared as described above for MTT 
assays and with CBZ treatments of 1-1000 µM, for 3-48 hours. LDH assays were conducted 
using a commercially available kit (Clontech, Mountain View, CA) following the 
manufacturer’s protocol. Wells containing 2% Triton X-100 were used as a positive control for 
total cell lysis. The release of LDH in the media was measured spectrophotometrically at 490 
nm using a plate reader ‘TopCount’ (Perkin Elmer, Ueberlingen, Germany). Cytotoxicity was 
calculated as a percentage LDH release relative to the positive controls. All assay points were 
performed in triplicate with each experiment containing 3 wells for each CBZ concentration 
3.3. Functional assays:  
The effect of CBZ on rCMECs function was assessed via an examination of CBZ on 
transcellular transport of Evans Blue, trans-endothelial potential difference (TEPD), and trans-
endothelial electrical resistance (TEER) , as described in a previous publications (Elmorsy et 
al., 2014). Briefly, cells were grown on a semi-permeable membrane in 24-well inserts (area 
0.6 cm2, Millicell, Millipore Corporation). After 72 hours, a stable TEER was established of 
approximately 22 Ω cm-2 (Supplementary Figure S1), a value consistent with other transwell 
studies (He et al., 2014; Srinivasan et al., 2015). Cells were then treated with CBZ over the 
concentration range of 0.1-100 µM and for 3-48 hours. TEER and TEPD were measured at the 
studied time points using a WPI EVOM resistance meter (WPI, UK). To assess endothelial cell 
transport properties, Evans blue (0.05 mg/ml) labelled albumin (4%) was added to the media 
in the treated and controls well inserts. The passage of labelled albumin through the endothelial 
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cell monolayer was determined by the infranatent by measuring Evan Blue absorbance at 620 
nm using a TopCount’ device (Perkin Elmer, Ueberlingen, Germany). All data points were 
performed in triplicate, and data combined from 3 separate experiments. 
3.4. Effect of CBZ on bioenergetics: 
3.4.1. Intracellular ATP measurements: Cells were prepared and treated as described above 
for MTT assays.  The levels of intracellular ATP were then measured based on luminescence 
of ATP according to a kit protocol (Ab113849, Abcam, Cambridge, UK). ATP levels were 
quantified relative to control well readings set at 100%. All data points were performed in 
triplicate, and data combined from 3 separate experiments. 
3.4.2. Mitochondrial complex activity measurements: Isolated rCMECs were cultured in 6 
well plates (4 x 103 cells/well) and grown until confluent, before treatment with CBZ (0.1-100 
µM, 3-48 hours). Cells were then homogenized and a mitochondrial-enriched fraction prepared 
according to Spinazzi et al. (2012). Briefly, cells were trypsinied, washed twice in PBS, 
centrifuged at 1000 x g for 5 minutes at 4˚C, then cell pellets flash-frozen in liquid nitrogen.  
After thawing, the pellet was resuspended in 1 mL of 10 mM ice-cold hypotonic Tris buffer 
(pH 7.6), and homogenized with a 2-mL glass/teflon tissue grinder. Two hundred µL of sucrose 
solution (1.5 M) was added, mixed, and the cell homogenate centrifuged at 600 x g for 10 min 
at 2˚C.  The supernatant was retained and centrifuged at 14,000 x g for 10 min at 2˚C. The 
mitochondrial pellet produced was then resuspended in 0.5 mL of 10 mM ice-cold hypotonic 
Tris buffer (pH 7.6), flash-frozen in liquid nitrogen, and stored at -80˚C until required. Protein 
concentration was measured using a Bradford assay. The mitochondrial solution was subjected 
to three cycles of freeze-thawing to disrupt the mitochondrial membranes prior to use.  For 
Complex I measurements, 25-40 µg of protein were used per assay, and for Complex III, 10-
20 µg of protein per assay. Complex I activities were assayed according to the protocol of 
Janssen et al. (2004). Dichloroindophenol (DCIP) was used as the terminal electron acceptor 
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as it is only reduced by Complex I.  Complex I activity was measured at 600 nm. Complex III 
activity was assayed according to the protocol of Spinazzi et al. (2012). Decylubiquinol (100 
µM) and Cytochrome c (75 µM) were the electron acceptors for Complex III assays, with 
activity measured at 550 nm. For calibration of mitochondrial complexes activities, rotenone 
(10 µM), and antimycin A (10 µg/mL) were used as specific inhibitors for Complexes I and 
III, respectively. Specific complex activity was calculated by comparing the measured 
fluorescence in the presence and absence of the specific complex inhibitor. Experiments were 
repeated at least 4 times for each treatment concentration. Specific complex enzyme activity 
(nmol min-1 mg-1) = (∆ Absorbance/min × 1,000)/[(extinction coefficient × volume of sample 
used in mL) × (sample protein concentration in mg mL-1)].  Extinction coefficient for DCIP = 
19.1 mM-1cm-1, extinction coefficient for reduced cytochrome c = 18.5 mM-1cm-1 (Spinazzi et 
al. 2012). 
3.4.3. Lactate production assays: Cells were seeded in 24-well plates at 5 x104 cells/well, and 
treated with CBZ (0.1-100 µM, 3-48 hours). Cells were trypsinized, and then spun at 1000 x g 
for 5 minutes. Pelleted cells were counted whereas the supernatant media was retained and 
assayed for lactate levels using a lactate assay kit (Biovision, Mountain View, California, USA) 
according to the manufacturer’s instructions. Lactate production was normalized to cell number 
and expressed as a percentage of control lactate production, as described previously (Al-Ghafari 
et al., 2019) All data points were performed in triplicate, and data combined from 3 separate 
experiments. The lactate contents of the controls were considered 100%.  
3.4.4. Measurements of oxygen consumption rate: The oxygen consumption rate (OCR) of 
rCMECs suspensions was measured polarographically using Clark oxygen electrodes (Rank 
Brothers, Bottisham, UK) by changes in PO2 tension within the chambers, as described by 
Elmorsy and Smith (2015). Cells were cultured in T25 flasks. Cells were treated with CBZ at 
0.1-100 µM, but for a single 24 hour incubation before cells were harvested, trypsinized, 
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centrifuged, and then resuspended in modified Hank’s solution and counted.  For OCR assays, 
basal OCR conditions were measured for 10 minutes prior to the addition of 2 µl of 6 mM azide 
to each chamber (12 µM, final concentration). Basal OCR was measured over a 300-sec period, 
whereas the azide slope was measured over 60 seconds after azide addition.  The PO2 changes 
were linear in all chambers. All assay data points were was conducted at least 5 times for every 
treatment concentration, and at 5 studied time points. 
3.4.5 Rhodamine-123 assay of mitochondrial membrane potential: Rhodamine-123 (Rh-123) 
is a lipophilic cationic dye localized to mitochondria depending on the mitochondrial 
membrane potential (MMP).  Mitochondria were prepared fresh and isolated and maintained 
in a buffer composed of sucrose (250 mM), HEPES (10 mM), K-EGTA (100 µM), MgCl2 (2 
mM), KH2PO4 (4 mM), pH 7.4 containing an ADP regenerating system (10 mM glucose and 
2.5 U hexokinase). Mitochondria were encased within a cuvette with continuous stirring in a 
spectrophotometer (F-7000, Hitachi, Chiyoda, Tokyo, Japan) at 25ºC. Rh-123 was added (50 
nM) and fluorescence monitored (excitation 503 nm, emission 527 nm). After 2 minutes CBZ 
was added to a final concentration of 10 µM, then increased to 100 µM for a further 2 minutes 
before addition of the mitochondrial inhibitor, antimycin A (1µg/ml). Experiments were 
repeated six times for each CBZ concentration. For each treatment concentration, fluorescence 
was measured 5 seconds before the next addition. 
3.5. Mitochondrial membrane fluidity and fatty acid composition: Cells were seeded in 6-
well plates at (4 x 103 cells/well), and treated with CBZ at 1-1000 µM for a single time point 
of 24 hours. Mitochondria were isolated following Spinazzi et al. (2012) for further evaluation 
of their mitochondrial membrane fluidity (MMF) and fatty acid content. To evaluate the effect 
of CBZ upon MMF, a trimethylammonium-diphenylhexatriene (TMA-DPH) fluorescent probe 
was used as described by Waczulikova et al. (2007) with modifications by Pérez-Hernández et 
al. (2017).  For the mitochondrial suspension, 0.5 mg protein/ml were labeled with TMA-DPH 
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at a final concentration of 0.25 mM. The samples were incubated in the dark for 30 min with 
stirring. Then the fluorescence polarization was measured in the same Perkin Elmer 
Fluorescence Spectrometer with excitation at 365 nm and emission at 425 nm. The 
measurements were performed from 10-60°C to assess the thermotropic characterization of 
treated and untreated mitochondrial membranes. Experiments were repeated five times for each 
concentration 
For evaluation of CBZ on the mitochondrial fatty acid composition, mitochondrial 
lipids were extracted following Oemer et al. (2018). Trans-esterification was conducted with 
boron trifluoride (14% (w/v) in methanol) (Morrison and Smith, 1964). The fatty acid 
composition of mitochondria was measured by gas chromatography (Hewlett Packard, 6890 
series) with a flame ionization detector (FID) using a 30 m. omegawax column (0.25 mm i.d., 
0.25 mm thickness) for separation of fatty acid methyl esters. The used carrier gas was ultra-
highly pure nitrogen (14 ml/min). The temperature was adjusted to 250°C for the injector and 
detector. For the column, the temperature program was adjusted to 180°C for 5 minutes with 
gradual increase in temperature (5°C/min) to a final temperature of 240°C, which was 
maintained for 18 min. A standard mixture of fatty acid methyl esters was injected for acyl 
chain identification in mitochondrial samples. Fatty acids composition is reported as mol%. 
The unsaturation index (U/S) was obtained from the total sum of unsaturated fatty acids divided 
by the total sum of saturated fatty acids. Experiments were repeated five times for each 
concentration. 
3.6. Statistical analysis:  
The concentration of agent producing 50% inhibition (IC50s) were calculated from a plot of log 
mole concentration (inhibitor or agonist) versus variable response curve, using nonlinear 
regression curve fitting models with best fit values. For MTT and ATP assays we adjusted 
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constraints of the bottom and top of the curve equal to zero and 100, with an assumption that 
the viability of the vehicle control was 100%, such that inhibition was at 0%. A Hill slope 
constraint equal to one was used for the fitting of the LDH data. For studying both the 
concentration and exposure duration effects, a two-way ANOVA was used with Bonferroni 
post-test for multiple comparisons. For a single comparison between drug treatments and 
control, a one-way ANOVA with Dunnet’s post-test was used. A Kruskall-Wallis one-way 
ANOVA with Dunn’s post-test was performed to consider statistical differences between the 
saturated/unsaturated fatty acid ratios. All statistical procedures were conducted using PRISM 
5 (GraphPad Software Inc., San Diego, CA), with a p-value of below 0.05 considered 
significant.  
4. Results: 
4.1. CBZ was cytotoxic to BBB endothelial cells: CBZ was cytotoxic to rCMECs in a 
concentrations and duration dependent pattern as assessed by MTT, LDH, and ATP assays 
(Figure 2). Significant cytotoxicity of CBZ was evidenced at concentrations above 1 µM after 
incubation for 3 hours (MTT and ATP assays), and 24 hours (LDH assays) (Supplementary 
Data, Tables S1-S3). The high sensitivity of ATP levels to therapeutic CBZ concentrations 
after a 3 hour exposure was mirrored at other time points; with ATP IC50 concentrations lower 
that those calculated for MTT assays (Table 1).  The half maximal effective concentration 
(EC50) for LDH assays was also calculated (Table 1). 
4.2. CBZ altered endothelial cell barrier function: CBZ exposure to endothelial cells altered 
their barrier function. CBZ significantly reduced migration of albumin across the monolayer 
of rCMECs at drug concentrations of ≥1 µM, after incubations of ≥6 hours (Figure 3A, and 
Supplementary Tables S4 and S5).  These changes correlated with increased ionic conductance 
(TEDP and TEER) (Figures 3B,C, and Supplementary Tables S4-S6). 
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4.3. CBZ reduced mitochondrial functionality: The effect of CBZ on mitochondrial functions 
were further investigated through an examination of mitochondrial complex I and complex III 
activities.  CBZ significantly inhibited both mitochondrial complexes I and III as early as 3 
hours post-exposure at concentrations of 0.1 and 10 µM, respectively (Figure 4 and 
Supplementary Data Table S2 and S3). An exposure of 0.1 µM was sufficient to significantly 
inhibit both mitochondrial complexes after a 24 hour exposure.  In parallel, CBZ significantly 
increased lactate production from a concentration of 0.1 µM after a 6 hour exposure (Figure 
5A, and Supplementary Data, Tables S2 and S3). Twenty-four hour oxygen consumption rates 
(OCRs) decreased in a concentrations dependent manner, significantly reduced by ≈50% after 
an exposure to 10 µM CBZ (Figure 5B).  
A Rh-123 assay was used to monitor mitochondrial membrane potential (MMP) and 
this this assessed after incubation with CBZ at exposures of 10, and 100 µM.  Cellular challenge 
with CBZ disrupted the MMP with a significant increase of Rh-123 fluorescence by 155% and 
245% with CBZ concentrations of 10 and 100µM, respectively, (Figure 6A,B).  Increase 
fluorescence was also established using the mitochondrial inhibitor, actimycin A (Figure 6A).  
A TMA-DPH assay was performed to consider the effect of CBZ on mitochondrial membrane 
fluidity (MMF), and this showed that CBZ significantly decreased the membrane fluidity of 
isolated mitochondria after a 24 hr treatment (Figure 6C). 
The effect of CBZ on the fatty acid compositions of mitochondria revealed that at high 
CBZ concentrations (100, and 1000 µM), there was a significant reduction of both saturated 
(palmitic and stearic fatty acids) and unsaturated fatty acids (palmitoleic, oleic, linoleic, 
arachidonic, and docosahexaenoic acid), and decrease of the unsaturated/saturated fatty acids 




This work was conducted to evaluate the toxicity of CBZ to isolated rCMECs. MTT, 
LDH, and ATP assays demonstrated that CBZ was cytotoxic to these cultured endothelial cells 
in a concentration and exposure duration dependent manner.  From a comparison of the CBZ 
inhibitor-concentration curves and associated IC50s (Figure 2 and Table 1), it was apparent that 
MTT metabolism, and moreover, ATP production, was sensitive to inhibition at relatively low 
CBZ concentrations.  The bioreduction of MTT to formazan is primarily attributed to 
mitochondrial based enzymes and electron carriers, although non-mitochondrial sites of 
bioreduction have also been localized (Bernas and Dobrucki, 2002).  ATP synthesis, via ATP 
synthase (complex V of the electron transport chain), is also mitochondrial (Kuhlbrant, 2015). 
Therefore, we hypothesised that the relative reduction of IC50 values for MTT and ATP assays 
(to those from LDH assays) was attributed to the damaging effects of CBZ to mitochondria, 
and this prompted us to evaluate this mechanism further. 
We studied the cytotoxic effects of CBZ over a broad concentration range of 0.1 µM to 
1 mM, concentrations that include previously reported therapeutic, supra-therapeutic, and toxic 
levels drug levels (Spiller et al., 1990; Hojer et al., 1993; Winek et al., 2001; Spiller, 2001).  
The benefit of including relatively high drug concentrations is that it can provide an insight to 
the adverse effects that arise from an overdose within the limited time frame operational for 
cell culture experiments. 
Other studies have also considered the neurotoxicity of CBZ to primary cells; be it rat 
cerebellar granular cells (Gao and Chang, 1992), rat hippocampal neurons (Ambrósio et al., 
2000; Araújo et al., 2004), or rat astrocytes (Pavone and Cardile, 2003).  These studies have 
demonstrated CBZ neurotoxicity, and induction of apoptosis particularly at relatively high 
exposure concentrations (100 µM or above).   One of the mechanisms of CBZ cytotoxicity is 
via induction of ROS and a reduction of cellular ATP production (Pavone and Cardile, 2003; 
Araújo et al., 2004; Li et al., 2010a,b; Shao et al., 2019; Elmorsy E, 2020), although this has 
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not been observed in all published studies; with CBZ even able to increase ATP levels in 
neuroblastoma cells (SH-SY5Y) and liver HepG2 cells (Araújo et al., 2004; Laville et al., 2004; 
Mannerström et al., 2006). 
We examined functional (barrier) properties of endothelial cells via the transport of 
albumin, and this was significantly impaired with CBZ concentrations of 1 µM and above. 
Reduced albumin transport was inversely correlated with increased ionic conductance (TEER) 
(Supplementary Table S2), as observed previously after treatment of endothelial cells with 
antipsychotic drugs (Elmorsy et al., 2014).  Paracellular transport of albumin could be lowered 
at high CBZ exposures due to a loss of barrier integrity, but we would expect the CBZ-induced 
depletion of cellular ATP to also limit ATP-driven albumin transcytosis (Smith and Borchardt, 
1989; Poduslo et al. 1994; Hervé et al. 2008; Srinivasan et al., 2015), and thereby contribute to 
reduced albumin flux. From an in vivo context, at therapeutic concentrations, CBZ may reduce 
functional integrity of BBB endothelial cells and therefore increase CNS levels of concurrently 
administered medication, a process that may promote further toxicity and induce ADRs (Albani 
et al., 1995; Jaramillo et al., 2014; Fricke-Galindo et al., 2018). 
We show that CBZ influenced MMP and significantly inhibited both mitochondrial 
complexes I and III, and at therapeutically relevant concentrations of 10 µM after only a 3 hour 
exposure.  We presume these reductions in activities of components of the ETC contributed to 
reduced ATP synthesis and therefore the depleted cellular ATP levels we observed.  This 
reduced bioenergetic activity was further evidenced by decreased OCRs and increased lactate 
production via anaerobic metabolism. Furthermore, medication-induced redox damage to 
mitochondria will likely promote further release of reactive free radicals, and instigate a 
positive loop of redox stress and cellular damage (Neustadt and Pieczenik 2008; Deavall et al., 
2012; Finsterer and Scorza, 2017).  Noteworthy, is that the administration of CBZ to epileptic 
children resulted in reduced ATP production from peripheral leukocytes (Berger et al., 2010), 
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and elevation of markers of redox stress when compared to a control group (Tutanc et al., 
2015); demonstrative of a CBZ effect on mitochondria and induction of oxidative stress in vivo.   
Lastly, we showed that CBZ significantly altered the levels of mitochondrial fatty acids. 
This may have been caused by inhibition of synthesis, altered lipid remodeling, or due to the 
vulnerability of fatty acids to lipid peroxidation after the release of toxic free radicals. We 
report a decrease of the U/S fatty acid ratio at the relatively high CBZ concentrations that typify 
extensive redox stress.  Hence, CBZ-induced damage to mitochondrial bioenergetics may be 
mediated via reduced MMP and coupling to ATP synthesis, but also through damage and 
changes to the mitochondrial membrane composition including lipid peroxidation (Schenkel 
and Bakovic, 2014; Elmorsy 2020).  
Consistent with its therapeutic employment, CBZ binds to voltage-gated sodium 
channels (Yang et al., 2010), and, as a tricyclic imipramine, can also compete with imipramine 
for binding to the serotonin transporter (Sarker et al., 2010).  However, to date, no specific 
binding sites of CBZ to channels or pores within mitochondria have been identified. 
In summary, our study provides an insight into the potential toxicity of CBZ across a 
concentration range that includes therapeutic as well as toxic concentrations, and specifically 
considers bioenergetics disruption as a component of the mechanism of toxicity.  The ability 
of CBZ to deplete ATP levels at relatively low concentrations may have particular functional 
consequences for ATP-driven transport of molecules across the BBB, since these transporters 
are essential to maintain the integrity of the CNS from hazardous chemicals, drugs, and toxins.  
It will certainly be interesting to consider in future studies if damage to mitochondria from 
CBZ links to any of the CBZ ADRs in vulnerable individuals.  Furthermore, it will be of 
importance to investigate if respiratory substrates such as hydroxybutyrate or coenzyme Q that 
bypass a damaged ETC, or administration of antioxidants (to combat CBZ-induced redox 
stress), provide useful means to supplement the current use of activated charcoal, or 
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extracorporeal therapy such as heamodialysis or plasmapheresis (Pilapil and Petersen 2008; 
Ghannoum et al., 2014), to treat CBZ intoxications. 
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Figures Legends: 
Fig. 1. Chemical structure of carbamazepine.  
Fig. 2. Cytotoxicity assays of CBZ at concentrations of 0.1, 1, 10, and 100 µM to rCMECs. 
Cell viability was assessed via reduction of MTT (A), LDH leakage (B), and intracellular ATP 
levels (C). Data shown represent means ± SD.  
Fig. 3. Functional effects of CBZ at concentrations of 0.1, 1, 10, and 100 µM on rCMECs 
barrier properties for 3, 6, 12, 24, and 48 hours. Barrier properties were assessed using an insert 
model of Evans Blue (EB) labelled albumin migration (A), trans-endothelial potential 
difference (TEPD) (B), and trans-endothelial electrical resistance (TEER) (C).  Data shown 
represent means ± SEM.  Interactions between variables (as assessed by two-way ANOVA) 
are included. 
Fig. 4. The effect of CBZ at concentrations of 0.1, 1, 10, and 100 µM on the mitochondrial 
complex I (MCI) (A) and complex III (MCIII) (B) activities of rCMECs. Data shown represent 
means ± SD. For significant changes from control: "c" = p<0.0001. Interactions between 
variables (as assessed by two-way ANOVA) are included. 
Fig. 5. The effect of CBZ at concentrations of 0.1, 1, 10, and 100 µM and exposures of 3-48 
hours on lactate production from rCMECs (A).  Oxygen consumption rates (OCR) after a 24 
hour CBZ exposure Interactions between variables (as assessed by two-way ANOVA) are 
included. (B). Data shown represent means ± SD. For significant changes from control: "a" = 
p<0.05, "c" = p<0.0001. 
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Fig. 6. The effect of CBZ at final concentrations of 10 and 100 µM on mitochondrial membrane 
potential (MMP) (A,B).  The effect of actimycin A, a mitochondrial inhibitor, upon the MMP 
was also demonstrated to verify mitochondrial viability (A). The effect of a 24 h exposure to 
CBZ on isolated mitochondria membrane fluidity was assessed by a TMA-DPH assay (C). 
Data shown represent means ± SD. For significant changes from control: "c" = p<0.0001. 
Interactions between variables (as assessed by two-way ANOVA) are included. 
Fig.7. The effect of CBZ at concentrations of 1, 10, 100, and 1000 µM on the mitochondrial 
membrane lipid contents of saturated (palmitic and stearic fatty acid) and unsaturated fatty 
acids (palmitoleic, oleic, linoleic, arachidonic, and docosahexaenoic acid), and the 
unsaturated/saturated fatty acids ratio (U/S ratio). Data shown represent means ± SD. For 
significant changes from control: "a" = p<0.05, "b" = p<0.001, "c" = p<0.0001. 
 
